NCT01428388

Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion

Comparison of Anti-vascular Endothelial Growth Factors Agents in the Treatment of Macular Edema Following Retinal Vein Occlusion

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Barnes Retina Institute · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Accepted

Summary

Antagonists of the vascular endothelial growth factor (VEGF) pathway are effective in treating macular edema resulting from retinal vein occlusion (RVO). In the eye, the two most widely used anti-VEGF agents are ranibizumab and bevacizumab. Only ranibizumab has been FDA-approved for the treatment of macular edema from RVO, however bevacizumab has been used off-label by many ophthalmologists with good success. Furthermore, the cost of bevacizumab is less than one-tenth the cost of ranibizumab. Here the investigators conduct a six month randomized, prospective interventional trial comparing the effectiveness of ranibizumab with bevacizumab in the treatment of macular edema from RVO. Primary outcome measures are change in central retinal thickness. Secondary measures are change in visual acuity from baseline and change in angiographic properties of macular lesions from baseline after treatment.

Conditions

• Retinal Vein Occlusion
• Macular Edema

Interventions

Type	Name	Description
DRUG	Intravitreal injection of bevacizumab	1.25 mg per dose, delivered monthly by intravitreal injection for six months
DRUG	Intravitreal injection of ranibizumab (0.5 mg per dose)	0.5 mg per dose, delivered monthly by intravitreal injection for six months

Timeline

• Start date: 2011-09-01
• Primary completion: 2015-10-01
• Completion: 2015-12-01
• First posted: 2011-09-05
• Last updated: 2017-10-27

Locations

1 site across 1 country: United States